Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Gains from Investment Securities (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Gains from Investment Securities for 10 consecutive years, with $27243.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 95.43% to $27243.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $27243.0, a 95.43% decrease, with the full-year FY2024 number at $587704.0, up 7.93% from a year prior.
  • Gains from Investment Securities was $27243.0 for Q3 2025 at Marker Therapeutics, down from $709261.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $7.5 million in Q1 2021 to a low of $1000.0 in Q1 2023.
  • A 5-year average of $1.1 million and a median of $592018.5 in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 99.96% in 2023, then skyrocketed 60036.9% in 2024.
  • Marker Therapeutics' Gains from Investment Securities stood at $7.5 million in 2021, then crashed by 88.17% to $886173.0 in 2022, then plummeted by 38.55% to $544532.0 in 2023, then grew by 7.93% to $587704.0 in 2024, then tumbled by 95.36% to $27243.0 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Gains from Investment Securities are $27243.0 (Q3 2025), $709261.0 (Q2 2025), and $140000.0 (Q1 2025).